Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Sold by EntryPoint Capital LLC

EntryPoint Capital LLC lowered its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 11.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 13,971 shares of the company’s stock after selling 1,833 shares during the quarter. EntryPoint Capital LLC’s holdings in Takeda Pharmaceutical were worth $185,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in TAK. Charles Schwab Investment Management Inc. boosted its holdings in shares of Takeda Pharmaceutical by 17.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 187,165 shares of the company’s stock valued at $2,661,000 after acquiring an additional 27,628 shares during the period. Cerity Partners LLC lifted its position in Takeda Pharmaceutical by 93.1% in the 3rd quarter. Cerity Partners LLC now owns 127,071 shares of the company’s stock valued at $1,807,000 after purchasing an additional 61,271 shares during the last quarter. FMR LLC boosted its stake in Takeda Pharmaceutical by 10.9% during the 3rd quarter. FMR LLC now owns 2,908,918 shares of the company’s stock valued at $41,365,000 after purchasing an additional 286,052 shares during the period. BNP Paribas Financial Markets grew its position in Takeda Pharmaceutical by 416.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company’s stock worth $46,000 after purchasing an additional 2,596 shares during the last quarter. Finally, Hantz Financial Services Inc. increased its stake in shares of Takeda Pharmaceutical by 3.2% in the third quarter. Hantz Financial Services Inc. now owns 226,685 shares of the company’s stock valued at $3,223,000 after purchasing an additional 6,967 shares during the period. 9.17% of the stock is currently owned by institutional investors.

Takeda Pharmaceutical Stock Performance

Shares of NYSE TAK opened at $15.06 on Friday. Takeda Pharmaceutical Company Limited has a 12-month low of $12.58 and a 12-month high of $15.31. The company has a market cap of $47.90 billion, a PE ratio of 37.64, a P/E/G ratio of 0.24 and a beta of 0.46. The stock has a 50 day simple moving average of $14.16 and a 200-day simple moving average of $13.92. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings results on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. On average, equities research analysts forecast that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.